Market News Video
MNV MNV 10 Bargains You Can Buy Cheaper Than Insiders Did
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Biogen Enters Oversold Territory (BIIB)
Friday, July 24, 12:09 PM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

Mylan (MYL) Shares Cross Below 200 DMA
Monday, July 27, 11:47 AM ET, by Market News Video Staff

In trading on Monday, shares of Mylan NV (MYL) crossed below their 200 day moving ...

Top Buys by Directors: Papadopoulos's $3M Bet on BIIB
Tuesday, July 28, 12:26 PM ET, by Market News Video Staff

The directors of a company tend to have a unique inside view into the business, ...

Alexion Pharmaceuticals Becomes #45 Most Shorted Nasdaq 100 Component, Replacing Wynn Resorts
Tuesday, July 28, 1:12 PM ET, by Market News Video Staff

The most recent short interest data has been released by the NASDAQ for the 07/15/2015 ...

Noteworthy ETF Outflows: RSP, CB, CELG, ALXN
Thursday, July 30, 11:10 AM ET, by Market News Video Staff

Symbols mentioned in this story: RSP, CB, CELG, ALXN Exchange traded funds (ETFs) trade just ...

  More articles:  1 2 3 4 5 6 7 next »

Bullish Two Hundred Day Moving Average Cross - ALXN

By Market News Video Staff, Wednesday, January 2, 2:03 PM ET
Play Video: Learn About The 200 DMA

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Wednesday, shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) crossed above their 200 day moving average of $97.88, changing hands as high as $99.65 per share. Alexion Pharmaceuticals Inc. shares are currently trading up about 6.1% on the day. The chart below shows the one year performance of ALXN shares, versus its 200 day moving average:

Alexion Pharmaceuticals Inc. 200 Day Moving Average Chart

Looking at the chart above, ALXN's low point in its 52 week range is $69.82 per share, with $119.54 as the 52 week high point that compares with a last trade of $99.34.

Special Offer: Manage the risks of the markets better with a free 30 day trial to the Multi-Asset Class Risk Management Portfolio.

According to the ETF Finder at ETF Channel, ALXN makes up 7.94% of the iShares Nasdaq Biotechnology Index Fund ETF (NASDAQ:IBB) which is trading higher by about 2.6% on the day Wednesday.

See what other ETFs contain ALXN
See what other stocks are held by IBB

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   ALXN   Above   According   Alexion   Asset   Biotechnology   Class   Crossing   Finder   Fund   Looking   Management   Pharmaceuticals   Special   Start   Stocks   Their   Wednesday   about   above   average   below   better   changing   chart   compares   currently   held   high   iShares   last   makes   markets   moving   other   point   range   raquo   share   shares   slideshow   that   trading   trial   versus   week   what   which   with   year
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Chart Zero Stock Market Game Stock Market Definitions

Bullish Two Hundred Day Moving Average Cross - ALXN | Market News Video | Copyright © 2008 - 2015, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.